Advances in Atopic Dermatitis and Chronic Hand Eczema: Delgocitinib and Tralokinumab

Abstract

This article summarizes selected poster presentations from the 2024 Fall Clinical Dermatology Conference (FCDC), with a focus on updated data for tralokinumab in atopic dermatitis (AD) and delgocitinib cream in chronic hand eczema (CHE), and how these treatments could tackle unmet needs. Presentations on the IL-13 receptor inhibitor tralokinumab included final data from the long-term, open-label extension study ECZTEND, of patients with moderate-to-severe AD exposed to tralokinumab for up to 6 years, as well as evaluations of the treatment’s long-term safety and efficacy in patients aged ≥65 years. An indirect comparison of tralokinumab and lebrikizumab indicated their efficacy was similarly maintained over 1 year. Real-world data for tralokinumab in AD were presented from several studies, including three interim analyses of the TRACE study, which assessed tralokinumab efficacy in AD on specific regions of the body. Delgocitinib cream is a topical pan-JAK inhibitor recently approved in the EU for moderate-to-severe CHE in adults for whom topical corticosteroids (TCS) are inadequate or inappropriate. Several posters presented data from a pooled post hoc analysis of Phase III trials DELTA 1 and DELTA 2, demonstrating that delgocitinib led to meaningful improvements in clinical signs and patient-reported outcomes, and was well-tolerated over 16 weeks of treatment. One poster showed that twice-daily application of delgocitinib cream 20 mg/g for 16 weeks resulted in minimal systemic exposure, and two reported favorable efficacy and safety of delgocitinib compared with systemic therapies, including data from the DELTA FORCE trial. Overall, presented data supported the benefits of delgocitinib as an efficacious and well-tolerated topical treatment in a patient population that faces a high disease burden and has unmet treatment needs.